Gurevich Vsevolod V, Gurevich Eugenia V
Department of Pharmacology, Vanderbilt University, Nashville, TN, United States.
Front Pharmacol. 2019 Feb 19;10:125. doi: 10.3389/fphar.2019.00125. eCollection 2019.
Every animal species expresses hundreds of different G protein-coupled receptors (GPCRs) that respond to a wide variety of external stimuli. GPCRs-driven signaling pathways are involved in pretty much every physiological function and in many pathologies. Therefore, GPCRs are targeted by about a third of clinically used drugs. The signaling of most GPCRs via G proteins is terminated by the phosphorylation of active receptor by specific kinases (GPCR kinases, or GRKs) and subsequent binding of arrestin proteins, that selectively recognize active phosphorylated receptors. In addition, GRKs and arrestins play a role in multiple signaling pathways in the cell, both GPCR-initiated and receptor-independent. Here we focus on the mechanisms of GRK- and arrestin-mediated regulation of GPCR signaling, which includes homologous desensitization and redirection of signaling to additional pathways by bound arrestins.
每个动物物种都表达数百种不同的G蛋白偶联受体(GPCR),这些受体对各种各样的外部刺激作出反应。GPCR驱动的信号通路几乎涉及每一种生理功能以及许多病理过程。因此,约三分之一的临床用药都以GPCR为靶点。大多数GPCR通过G蛋白进行的信号传导通过特定激酶(GPCR激酶,即GRK)对活性受体的磷酸化作用以及随后抑制蛋白的结合而终止,抑制蛋白可选择性识别活性磷酸化受体。此外,GRK和抑制蛋白在细胞内的多种信号通路中发挥作用,包括GPCR启动的信号通路和不依赖受体的信号通路。在这里,我们重点关注GRK和抑制蛋白介导的GPCR信号调节机制,其中包括同源脱敏以及结合的抑制蛋白将信号重定向至其他通路。